• 1
    Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853906.
  • 2
    National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41 (Suppl. 3): S1S91.
  • 3
    National Kidney Foundation Kidney. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1S266.
  • 4
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 24862497.
  • 5
    United States Renal Data System. USRDS 2000 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. 12th Annual Report. Bethesda, MD: Division of Kidney, Urologic, and Hematological Diseases, National Institute of Diabetes and Digestive Kidney Diseases, National Institues of Health, 2000.
  • 6
    Anonymous. National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 525584.
  • 7
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607617.
  • 8
    Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO (4), Ca x PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 21312138.
  • 9
    Massy ZA, Chadefaux-Vekemans B, Chevalier A et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 11031108.
  • 10
    Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93103.
  • 11
    Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 25542558.
  • 12
    Jungers P, Chauveau P, Bandin O et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 1997; 23: 170173.
  • 13
    Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138141.
  • 14
    Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst (e) ine the missing link? Nephrol Dial Transplant 1999; 14: 19341942.
  • 15
    Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134137.
  • 16
    Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular oucomes in hemodialysis patients. Kidney Int 2002; 61: 609614.
  • 17
    Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 18991911.
  • 18
    Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648658.
  • 19
    Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre–dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15: 16241630.
  • 20
    Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469476.
  • 21
    Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumoniae infection – long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 809815.
  • 22
    Holdaas H, Fellström B, Jardine A et al. Prevention of cardiac death and non-fatal coronary events with fluvastatin in renal transplant patients: a mulicentre randomised placebo controlled trial. Lancet 2003; 361: 202431.
  • 23
    Anonymous. The Sixth Report Of The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 24132446.
  • 24
    American Diabetes Association. Clinical practice recommendations. Diabetes Care 2002; 25 (Suppl. 1): 2AD.
  • 25
    Mosca L, Collins P, Herrington DM et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499503.
  • 26
    U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendaion and rationale. Ann Intern Med 2002; 136: 157160.
  • 27
    Krauss RM, Eckel RH, Howard B et al. AHA Dietary Guidelines: revision. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 22842299.
  • 28
    Smith SC Jr, Blair SN, Bonow RO et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease. update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 15771579.
  • 29
    Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic Stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163182.
  • 30
    The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. JAMA 2000; 283: 32443254.
  • 31
    MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 722.
  • 32
    Macmahon M, Kirkpatrick C, Cummings CE et al. A pilot study with simvastatin and folic acid/vitamin B12 for the Study Of The Effectiveness Of Additional Reductions In Cholesterol and Homocysteine (SEARCH). Nutr Metabol Cardiovasc Dis 2000; 10: 195203.
  • 33
    Brown WV. Cholesterol lowering in atherosclerosis. Am J Cardiol 2000; 86: 29H32H.
  • 34
    Gotto AM. Ongoing clinical trials of statins. Am J Cardiol 2001; 88 (Suppl.): 36F40F.
  • 35
    Isaacsohn JL, Davidson MH, Hunninghake D, Singer R, Mclain R, Black DM. Aggressive Lipid-Lowering Initiative Abates New Cardiac Events (ALLIANCE): rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol 2000; 86: 250252.
  • 36
    Cannon CP, Mccabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002; 89: 860861.
  • 37
    Shepherd J, Blauw GJ, Murphy MB et al. The design of a Prospective Study Of Pravastatin In The Elderly At Risk (PROSPER). Am J Cardiol 1999; 84: 11921197.
  • 38
    Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000; 23 (Suppl. 2): B49B53.
  • 39
    Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 1999; 71: S222S226.
  • 40
    Diercks GF, Janssen WM, Van Boven AJ et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000; 86: 635638.
  • 41
    Larosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 23402346.
  • 42
    Sacks FM, Tonkin AM, Shepherd J et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The prospective pravastatin pooling project. Circulation 2000; 102: 1900.
  • 43
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614620.
  • 44
    the Long-term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 13491357.
  • 45
    Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The CARE Investigators. Circulation 1998; 98: 25132519.
  • 46
    Ghanem H, Van Den Dorpel MA, Weimar W, Man in ‘t Veld AJ, El-Kannishy MH, Jansen H. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996; 49: 488493.
  • 47
    Van Den Dorpel MA, Ghanem H, Rischen-Vos J, Man in ‘t Veld AJ, Jansen H, Weimar W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997; 51: 16081612.
  • 48
    Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl 1999; 71: S235S237.
  • 49
    Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158165.
  • 50
    Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 1998; 30: 777788.
  • 51
    Aakhus S, Dahl K, Widerøe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648654.
  • 52
    Kasiske BL, Chakkera H, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 17351743.
  • 53
    Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: Natural history and response to treatment. Medicine 1994; 73: 215223.
  • 54
    Barbagallo CM, Pinto A, Gallo S et al. Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma lipoproteins. Transplantation 1999; 67: 366371.
  • 55
    Roodnat JI, Mulder PG, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 17041710.
  • 56
    Massy ZA, Mamzer-Bruneel MF, Chevalier A et al. Carotid atherosclerosis in renal transplant recipients. Nephrol Dial Transplant 1998; 13: 17921798.
  • 57
    Biesenbach G, Margreiter R, Konigsrainer A et al. Comparison of progression of macrovascular diseases after kidney or pancreas and kidney transplantation in diabetic patients with end-stage renal disease. Diabetologia 2000; 43: 231234.
  • 58
    Scanferla F, Toffoletto PP, Roncali D, Bazzato G. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. Am J Hypertens 1991; 4: 868.
  • 59
    Hommel E, Andersen P, Gall M-A et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35: 447451.
  • 60
    Nielsen S, Schmitz O, Mæller N et al. Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 10791086.
  • 61
    Thomas ME, Harris KPG, Ramaswamy C et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993; 44: 11241129.
  • 62
    Aranda Arcas JL, Sanchez R, Guijarro C et al. [Effect of pravastatin on hypercholesterolemia associated with proteinuria]. Ann Med International 1994; 11: 523527.
  • 63
    Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604609.
  • 64
    Rayner BL, Byrne MJ, Van Zyl Smit R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 1996; 46: 219224.
  • 65
    Smulders YM, Van Eeden AE, Stehouwer CDA, Weijers RNM, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27: 9971002.
  • 66
    Tonolo G, Ciccarese M, Brizzi P et al. Reduction of albumin excretion rate in normotensive microalbumiuric type 2 diabetic pateints during long-term simvastatin treatment. Diabetes Care 1997; 20: 18911895.
  • 67
    Olbricht CJ, for the Simvastatin in Nephrotic Syndrome Study Group. Simvastatin in nephrotic syndrome. International Symposium on Lipids and Renal Disease, Kashikojima, Japan, 1999.
  • 68
    Nishimura M, Sasaki T, Oishi A et al. Angiotensin converting enzyme inhibitor and probucol suppress time-dependent increase in urinary type IV collagen excretion of NIDDM with early nephropathy. J Am Soc Nephrol 1999; 10: 131A.
  • 69
    Buemi M, Allegra A, Corica F et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67: 427431.
  • 70
    Fried LF, Orchard TJ, Kasiske BL. The effect of lipid reduction on renal disease progression: a meta-analysis. Kidney Int 2001; 59: 260269.
  • 71
    Katznelson S, Wilkinson AH, Kobashigawa JA et al. The effect of pravastatin on acute rejection after kidney transplantation – A pilot study. Transplantation 1996; 61: 14691474.
  • 72
    Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72: 223227.
  • 73
    Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney Int 2001; 60: 199097.
  • 74
    Sahu K, Sharma R, Gupta A et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant 2001; 15: 173175.
  • 75
    Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164173.
  • 76
    Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 19081919.
  • 77
    Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 9981004.
  • 78
    Klein R, Klein BE, Moss SE, Cruickshank KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999; 22: 743751.
  • 79
    Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Progression of diabetic nephropathy. Kidney Int 1997; 59: 702709.
  • 80
    Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2397.
  • 81
    Samuelsson O, Attman PO, Knight-Gibson C et al. Plasma levels of lipoprotein (a) do not reflect progression of human chronic renal failure. Nephrol Dial Transplant 1996; 11: 22372243.
  • 82
    Yokoyama H, Tomonaga O, Hirayama M et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405411.
  • 83
    Samuelsson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 19081915.
  • 84
    Nielsen S, Schmitz A, Rehling M, Mogensen CE. The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 1997; 241: 133141.
  • 85
    Gall M-A, Nielsen FS, Smidt UM. Parving H-H. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993; 36: 10711078.
  • 86
    Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 1991; 337: 12991304.
  • 87
    Dillon IJ. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis 1993; 22: 802.
  • 88
    Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9: 10971102.
  • 89
    Toth T, Takebayashi S. Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis. Int Urol Nephrol 1994; 26: 93106.
  • 90
    Aakhus S, Dahl K, Widerøe TE. Hyperlipidaemia in renal transplant patients. J Intern Medical 1996; 239: 407415.
  • 91
    Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clinic Proc 1992; 67: 653657.
  • 92
    Brown JH, Murphy BG, Douglas AF et al. Influence of immunosuppressive therapy on lipoprotein (a) and other lipoproteins following renal transplantation. Nephron 1997; 75: 277282.
  • 93
    Moore R, Thomas D, Morgan E et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc 1993; 25: 10601061.
  • 94
    Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn W, Scharer K. Lipoprotein (a) serum levels and apolipoprotein (a) phenotypes in children with chronic renal disease. Pediatr Res 1993; 34: 772776.
  • 95
    Silverstein DM, Palmer J, Polinsky MS, Braas C, Conley SB, Baluarte HJ. Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr Nephrol 2000; 14: 105110.
  • 96
    Goldstein S, Duhamel G, Laudat MH et al. Plasma lipids, lipoproteins and apolipoproteins AI, AII. and B in renal transplanted children: what risk for accelerated atherosclerosis? Nephron 1984; 38: 8792.
  • 97
    Van Gool S, Van Damme-Lombaerts R, Cobbaert C, Proesmans W, Eggermont E. Lipid and lipoprotein abnormalities in children on hemodialysis and after renal transplantation. Transplant Proc 1991; 23: 13751377.
  • 98
    Milliner DS, Morgenstern BZ, Murphy M, Gonyea J, Sterioff S. Lipid levels following renal transplantation in pediatric recipients. Transplant Proc 1994; 26: 112114.
  • 99
    Singh A, Tejani C, Benfield M, Tejani A. Sequential analysis of the lipid profile of children post-renal transplantation. Pediatr Transplant 1998; 2: 216223.
  • 100
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112S119.
  • 101
    Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002; 141: 191197.
  • 102
    Strong JP, Malcom GT, Mcmahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727735.
  • 103
    Antikainen M, Sariola H, Rapola J, Taskinen M-R, Holthöfer H, Holmberg C. Pathology of renal arteries of dyslipidemic children with congenital nephrosis. APMIS 1994; 102: 129134.
  • 104
    Nayir A, Bilge I, Kilicaslan I, Ander H, Emre S, Sirin A. Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant 2001; 16: 20412047.
  • 105
    Olson RE. Atherogenesis in children. implications for the prevention of atherosclerosis. Adv Pediatr 2000; 47: 5578.
  • 106
    National Heart LaBI. The Lipid Research Clinics Population Studies Data Book, vol 1: the Prevalence Study. Bethesda, MD: US Department of Health and Human Services 1980: NIH Pub no. 801527.
  • 107
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 108
    Nauck M, Kramer-Guth A, Bartens W, Marz W, Wieland H, Wanner C. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Clin Nephrol 1996; 46: 319325.
  • 109
    Bairaktari E, Elisaf M, Tzallas C et al. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients (1). Clin Biochem 2001; 34: 593602.
  • 110
    Sentí M, Pedro-Botet J, Noguës X, Rubiës-Prat J. Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. Clin Chem 1991; 37: 13941397.
  • 111
    Ticho BS, Neufeld EJ, Newburger JW, Harris N, Baker A, Rifai N. Utility of direct measurement of low-density lipoprotein cholesterol in dyslipidemic pediatric patients. Arch Pediatr Adolesc Med 1998; 152: 787791.
  • 112
    Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, Mcnamara PM, Dalen JE. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol 1984; 54: 722725.
  • 113
    Ryder REJ, Hayes TM, Mulligan IP, Kingswood JC, Willimas S, Owens DR. How soon after myocardial infarction should plasma lipid values be assessed? BMJ 1984; 289: 16511653.
  • 114
    Henkin Y, Crystal E, Goldberg Y et al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol 2002; 89: 711.
  • 115
    Mendez I, Hachinski V, Wolfe B. Serum lipids after stroke. Neurology 1987; 37: 507511.
  • 116
    Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med 1969; 281: 10811086.
  • 117
    Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986; 32: 142145.
  • 118
    Sammalkorpi K, Valtonen V, Kerttula Y, Nikkilä E, Taskinen M-R. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37: 859865.
  • 119
    Figueroa O, Franco-Saenz R, Mulrow PJ, Montesinos E. Changes in cholesterol levels after coronary artery bypass surgery. Am J Med Sci 1992; 303: 7377.
  • 120
    Aufenanger J, Walter H, Kattermann R. [Studies of lipid and lipoprotein metabolism in man after surgical interventions]. Langenbecks Arch Chir 1993; 378: 4148.
  • 121
    Akgun S, Ertel NH, Mosenthal A, Oser W. Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 1998; 131: 103108.
  • 122
    Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol 1991; 10: 261267.
  • 123
    Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 5964.
  • 124
    Kasiske BL, Heim-Duthoy KL. Transient reductions in serum cholesterol after renal transplantation. Am J Kidney Dis 1992; 20: 387393.
  • 125
    Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11: S1.
  • 126
    Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834841.
  • 127
    Mccune TR, Thacker LRII, Peters TG et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998; 65: 8792.
  • 128
    Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclsporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 13521359.
  • 129
    Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982; 22: 4247.
  • 130
    Hollander AA, Hene RJ, Hermans J, Van Es LA, Van Der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8: 294301.
  • 131
    Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo) lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5: 20732081.
  • 132
    John GT, Dakshinamurthy DS, Jeyaseelan L, Jacob CK. The effect of cyclosporin A on plasma lipids during the first year after renal transplantation. Natl Med J India 1999; 12: 1417.
  • 133
    Kupin W, Venkat KK, Oh HK, Dienst S. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 5355.
  • 134
    Ingulli E, Tejani A, Markell M. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children postTransplantation in the cyclosporine ERA. Transplantation 1993; 55: 10291033.
  • 135
    Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 18: 353358.
  • 136
    Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin) -based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 10361042.
  • 137
    Hoogeveen RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 12441250.
  • 138
    Joven J, Villabona C, Vilella E, Masana L, Albert IR, Vallës M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990; 323: 579584.
  • 139
    Joven J, Espinel E, Simo JM, Vilella E, Camps J, Oliver A. The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia. Atherosclerosis 1996; 126: 243252.
  • 140
    Kaysen GA, Don B, Schambelan M. Proteinuria, albumin synthesis and hyperlipidaemia in the nephrotic syndrome. Nephrol Dial Transplant 1991; 6: 141149.
  • 141
    Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991; 40: 129138.
  • 142
    Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low-density lipoprotein metabolism and its association to plasma lipoprotein (a) in the nephrotic syndrome. Eur J Clin Invest 1997; 27: 169177.
  • 143
    Demant T, Mathes C, Gütlich K et al. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 1998; 54: 20642080.
  • 144
    O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68: 860866.
  • 145
    Tsimihodimos V, Bairaktari E, Tzallas C, Miltiadus G, Liberopoulos E, Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 1999; 9: 365368.
  • 146
    Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 2001; 155: 195200.
  • 147
    Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabet Metab 1999; 25 (Suppl. 3): 3240.
  • 148
    Best JD, O'Neal DN. Diabetic dyslipidaemia: current treatment recommendations. Drugs 2000; 59: 11011111.
  • 149
    Betteridge DJ. Diabetic dyslipidaemia. Diabet Obes Metab 2000; 2 (Suppl. 1): S31S36.
  • 150
    Avogaro P, Cazzolato G. Changes in the composition and physico-chemical characteristics of serum lipoproteins during ethanol-induced lipaemia in alcoholic subjects. Metab Clin Exp 1975; 24: 12311242.
  • 151
    Castelli WP, Doyle JT, Gordon T et al. Alcohol and blood lipids. The cooperative lipoprotein phenotyping study. Lancet 1977; 2: 153155.
  • 152
    Lifton L, Scheig R. Ethanol-induced hypertriglyceridemia. Prevalence and contributing factors. Am J Clin Nutr 1978; 31: 614618.
  • 153
    Marth E, Cazzolato G, Bittolo BG, Avogaro P, Kostner GM. Serum concentrations of Lp (a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab 1982; 26: 5662.
  • 154
    Taskinen MR, Nikkila EA, Valimaki M et al. Alcohol-induced changes in serum lipoproteins and in their metabolism. Am Heart J 1987; 113: 458464.
  • 155
    Seidel D. Hyperlipoproteinemias and liver disease. Adv Exp Medical Biol 1973; 38: 143153.
  • 156
    Muller P, Felin R, Lambrecht J et al. Hypertriglyceridaemia secondary to liver disease. Eur J Clin Invest 1974; 4: 419428.
  • 157
    Iglesias A, Arranz M, Alvarez JJ et al. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. Clin Chim Acta 1996; 248: 157174.
  • 158
    Flynn WJ, Freeman PG, Wickboldt LG. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. Ann Int Med 1987; 107: 63.
  • 159
    Tangrea JA, Adrianza E, Helsel WE et al. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The Isotretinoin-Basal Cell Carcinomas Study Group. Cancer Epidemiol Biomarkers Prev 1993; 2: 375380.
  • 160
    Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P. Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metabol Res Rev 2001; 17: 391395.
  • 161
    Luoma PV, Myllyla VV, Sotaniemi EA, Hokkanen TE. Plasma HDL cholesterol in epileptics with elevated triglyceride and cholesterol. Acta Neurol Scand 1979; 60: 5663.
  • 162
    Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997; 33: 242245.
  • 163
    Papacostas S. Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities. J Child Neurol 2000; 15: 138140.
  • 164
    Dube MP, Sprecher D, Henry WK et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 12161224.
  • 165
    Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV–infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001; 12: 463468.
  • 166
    Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001; 27: 443449.
  • 167
    Kasiske BL, Ma JZ, Kalil RSN, Louis TA. Effects of antihypertensive agents on serum lipids. Ann Intern Med 1995; 122: 133141.
  • 168
    Webb OL, Laskarzewski PM, Glueck CJ. Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabol Clin Exp 1984; 33: 971975.
  • 169
    Thompson PD, Cullinane EM, Sady SP et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 11651168.
  • 170
    Teruel JL, Lasuncion MA, Rivera M et al. Nandrolone decanoate reduces serum lipoprotein (a) concentrations in hemodialysis patients. Am J Kidney Dis 1997; 29: 569575.
  • 171
    Castelo-Branco C, Vicente JJ, Figueras F et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000; 34: 161168.
  • 172
    Van Stiphout WA, Grobbee DE, Hofman A, De Bruijn AM. Do oral contraceptives increase blood pressure and serum total cholesterol in young women? Prev Med 1990; 19: 623629.
  • 173
    Flint PM, Lapane KL, Barbour MM, Derby CA, Carleton RA, Hume AL. Cardiovascular risk profiles of oral contraceptive users and nonusers: a population-based study. Prev Med 1995; 24: 586590.
  • 174
    Connelly PW, Stachenko S, Maclean DR, Petrasovits A, Little JA. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999; 15: 419427.
  • 175
    Vierhapper H, Nardi A, Grosser P, Raber W, Gessl A. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid 2000; 10: 981984.
  • 176
    Keilani T, Schlueter WA, Levin ML, Batlle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993; 118: 246254.
  • 177
    Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907910.
  • 178
    Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 16111616.
  • 179
    Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185192.
  • 180
    Coggins CH, Dwyer JT, Greene T, Petot G, Snetselaar LG, Van Lente F. Serum lipid changes associated with modified protein diets: results from the feasibility phase of the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1994; 23: 514523.
  • 181
    Borchhardt K, Haas N, Yilmaz N et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52: 16221625.
  • 182
    Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862868.
  • 183
    Takahara S, Moriyama T, Kokado Y et al. Randomized prospective study of effects of benazapril in renal transplantation: an analysis of safety and efficacy. Clin Exp Nephrol 2002; 6: 242247.
  • 184
    Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine- treated renal transplants. Kidney Int 1993; 43: 419425.
  • 185
    Van Der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995; 25: 7781.
  • 186
    Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril. Transplantation 2001; 72: 17871792.
  • 187
    Martinez-Castelao A, Hueso M, Sanz V et al. Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. Transplant Proc 2002; 34: 403406.
  • 188
    Yu, -et al. Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999; 69: 632646.
  • 189
    Nutrition Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/Doqi). Kidney Disease Outcomes quality initiative clinical practice gudielines for nutrition in chronic renal failure. Am J Kidney Dis 2000; 35: S1S140.
  • 190
    NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA 1996; 276: 241246.
  • 191
    Castaneda C, Grossi L, Dwyer J. Potential benefits of resistance exercise training on nutritional status in renal failure. J Ren Nutr 1998; 8: 210.
  • 192
    Wenger NK. Lipid metabolism, physical activity, and postmenopausal hormone therapy. Am J Kidney Dis 1998; 32: S80S88.
  • 193
    Halbert JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 1999; 53: 514522.
  • 194
    Bennett WM, Carpenter CB, Shapiro ME et al. Delayed omega-3 fatty acid supplements in renal Transplantation. A double-blind, placebo-controlled study. Transplantation 1995; 59: 352356.
  • 195
    Urakaze M, Hamazaki T, Yano S, Kashiwabara H, Oomori K, Yokoyama T. Effect of fish oil concentrate on risk factors of cardiovascular complications in renal Transplantation. Transplant Proc 1989; 21: 21342136.
  • 196
    Maachi K, Berthoux P, Burgard G, Alamartine E, Berthoux F. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal Transplantation under triple immunosuppressive therapy. Transplant Proc 1995; 27: 846849.
  • 197
    Arnadottir M, Eriksson L-O, Germershausen JI, Thysell H, Eriksson LO. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in cyclosporine-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68: 5762.
  • 198
    Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993; 8: 637641.
  • 199
    Castro R, Queiròs J, Fonseca I et al. Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrol Dial Transplant 1997; 12: 21402143.
  • 200
    Kliem V, Wanner C, Eisenhauer T et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc 1996; 28: 31263128.
  • 201
    Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990; 49: 95100.
  • 202
    Renders L, Mayer-Kadner I, Koch C et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001; 16: 141146.
  • 203
    Santos AF, Keitel E, Bittar AE et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc 2001; 33: 11941195.
  • 204
    Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Stroke 2002; 33: 23372341.
  • 205
    Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997; 37: 816819.
  • 206
    Halstenson CE, Triscari J, Devault A, Shapiro B, Keane W, Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impariment. J Clin Pharmacol 1992; 32: 124132.
  • 207
    Gehr TWB. Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997; 53: 117121.
  • 208
    Quérin S, Lambert R, Cusson JR et al. Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 1991; 50: 437441.
  • 209
    Mazzu AL, Lettieri JT, Kelly E et al. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults. Eur J Clin Pharmacol 2000; 56: 6974.
  • 210
    Lesne M, Sturbois X, Mercier M. Etude pharmacocinetique comparative de deux formes galeniques d'acide nicitinique. Pharmaceutica Acta Helvetica 1976; 51: 367370.
  • 211
    Abshagen U, Kösters W, Kaufman B, Lang PD. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure. Klin Wochenschr 2001; 58: 889896.
  • 212
    Anderson P, Norbeck HE. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. Eur J Clin Pharmacol 1981; 21: 209214.
  • 213
    Williams AJ, Baker F, Walls J. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. Br J Clin Pharmacol 1984; 18: 361367.
  • 214
    Goldberg AP, Sherrard DJ, Haas LB, Brunzell JD. Control of clofibrate toxicity in uremic hypertriglyceridemia. Clin Pharmacol Ther 1977; 21: 317325.
  • 215
    Viikari J, Anttila M, Kasanen A. The use of clofibrate in patients with renal insufficiency. Int J Clin Pharmacol Ther Toxicol 1983; 21: 7780.
  • 216
    Merk W, Graben N, Hartmann H, Nikolaus C, Schlierf G, Schwandt P. Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees – a multicenter study. Int J Clin Pharmacol Ther Toxicol 1987; 25: 5962.
  • 217
    Desager JP, Costermans J, Verberckmoes R, Harvengt C. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982; 31: 5154.
  • 218
    Knauf H, Kolle EU, Mutschler E. Gemfibrozil absorption and elimination in kidney and liver disease. Klin Wochenschr 1990; 68: 692698.
  • 219
    Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 1987; 27: 9941000.
  • 220
    Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 195965.
  • 221
    Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE I. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 6470.
  • 222
    Gotto AM, Farmer JA. Pleitropic effects of statins: do they matter? Curr Opin Lipidol 2001; 12: 391394.
  • 223
    Munford RS. Statins and the acute-phase response. N Engl J Med 2001; 344: 20162018.
  • 224
    Simpson RJ Jr. Placing PRINCE in perspective. JAMA 2001; 286: 9193.
  • 225
    Park JW, Siekmeier R, Lattke P et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 2001; 6: 351361.
  • 226
    Åsberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in reanl transplant recipients. Am J Transplant 2001; 1: 382386.
  • 227
    Mück W, Mai I, Fritsche L et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251261.
  • 228
    Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl- glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporine. Nephron 1993; 65: 410413.
  • 229
    Ichimaru N, Takahara S, Kokado Y et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417423.
  • 230
    Velosa JA, La Belle P, Ronca PD. et al. Pharmacokinetics of lovastatin in renal transplant patients on azathioprine or cyclosporine. J Am Soc Nephrol 1990; 1: 325 (Abstract).
  • 231
    Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements. Variations and practical utility. JAMA 1992; 267: 16521660.
  • 232
    Olbricht C, Wanner C, Eisenhauer T et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311321.
  • 233
    Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 15591564.
  • 234
    Kovarik JM, Hartmann S, Hubert M et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002; 42: 222228.
  • 235
    Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39: 501504.
  • 236
    Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177182.
  • 237
    Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 5865.
  • 238
    Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68: 391400.
  • 239
    Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 5461.
  • 240
    Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 4953.
  • 241
    Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332341.
  • 242
    Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56: 225229.
  • 243
    Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369377.
  • 244
    Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267274.
  • 245
    Ziviani L, Da Ros L, Squassante L, Milleri S, Cugola M, Iavarone LE. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol 2001; 51: 147152.
  • 246
    Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997; 277: 296297.
  • 247
    Alderman CP. Possible interaction between nefazodone and pravastatin. Ann Pharmacother 1999; 33: 871.
  • 248
    Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118127.
  • 249
    Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397402.
  • 250
    Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice–simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477483.
  • 251
    Ditusa L, Luzier AB. Potential interaction between troglitazone and atorvastatin. J Clin Pharm Ther 2000; 25: 279282.
  • 252
    Lin JC, Ito MK. A drug interaction between troglitazone and simvastatin. Diabetes Care 1999; 22: 21042106.
  • 253
    Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592597.
  • 254
    Nakai A, Nishikata M, Matsuyama K, Ichikawa M. Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Bio Pharm Bull 1996; 19: 12311233.
  • 255
    Wen X, Wang J-S, Backman JT, Kivstö KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29: 13591361.
  • 256
    Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122129.
  • 257
    Pan W-J, Gustavson LE, Achari R et al. Lack of a clinicallly significant pharmacokinenic interaction between fenofibrate and pravstatin in healthy volunteers. J Clin Pharmacol 2000; 40: 316323.
  • 258
    Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340345.
  • 259
    Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80A83A.
  • 260
    Hunninghake D, Insull Wjr Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158: 407416.
  • 261
    Braunlin W, Zhorov E, Guo A et al. Bile acid binding to sevelamer HCl. Kidney Int 2002; 62: 611619.
  • 262
    Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine in the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20: 2730.
  • 263
    Jensen RA, Lal SM, Diaz-Arias A et al. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J 1995; 41: M704M706.
  • 264
    Kosoglou T, Meyer I, Veltri EP et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54: 309319.
  • 265
    Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 10841091.
  • 266
    Davidson MH, Mcgarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 21252134.
  • 267
    Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418424.
  • 268
    Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 6671.
  • 269
    Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245252.
  • 270
    Austin MA, Hokanson JE, Edwards, KL Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B12B.
  • 271
    Assmann G, Schulte H, Funke H, Von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998; 19 (Suppl. M): M8M14.
  • 272
    Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 14131419.
  • 273
    Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 1993; 104: 159171.
  • 274
    The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60: 427439.
  • 275
    Anonymous. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894903.
  • 276
    Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care 1999; 22 (Suppl. 2): B35B39.
  • 277
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 278
    Lageder H. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia]. Wien Klin Wochenschr 1980; 92: 95101.
  • 279
    Dick TB, Marples J, Ledermann HM, Whittington J. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. Curr Medical Res Opin 1981; 7: 489502.
  • 280
    Mertz DP, Lang PD, Vollmar J. Bezafibrate: lack of effect on creatinine excretion and muscular proteins. Res Exper Med 1982; 180: 9598.
  • 281
    Olsson AG, Lang PD, Vollmar J. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. Atherosclerosis 1985; 55: 195203.
  • 282
    Barbir M, Hunt B, Kushwaha S et al. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol 1992; 70: 15961601.
  • 283
    Lipkin GW, Tomson CRV. Severe reversible renal fairlue with bezafibrate. Lancet 1993; 341: 371.
  • 284
    Bruce R, Daniels A, Cundy T. Renal function changes in diabetic nephropathy induced by bezafibrate. Nephron 1996; 73: 490.
  • 285
    Hirai M, Tatuso E, Sakurai M, Ichikawa M, Matsuya F, Saito Y. Elevated blood concentrations of cyclosporine and kidney failure after bezafibrate in renal graft recipient. Ann Pharmacother 1996; 30: 883884 (Letter).
  • 286
    Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only inonocuous agent? Nephrol Dial Transplant 2000; 15: 19931999.
  • 287
    Devuyst O, Goffin E, Pirson Y, Van Ypersele de Strihou Ch. Creatinine rise after fibrate therapy in renal graft recipients. Lancet 1993; 341: 840.
  • 288
    Rössner S, Orö L. Fenofibrate therapy of hyperlipoproteinaemia. A dose–response study and a comparison with clofibrate. Atherosclerosis 1981; 38: 273282.
  • 289
    Rouffy J, Chanu B, Bakir R, Djian F, Goy-Loeper J. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis 1985; 54: 273281.
  • 290
    De Lorgeril M, Boissonnat P, Bizollon CA et al. Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. Eur J Clin Pharmacol 1992; 43: 161165.
  • 291
    Boissonnat P, Salen P, Guidollet J et al. The long-term effects of the lipid-lowering agent fenobibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58: 245247.
  • 292
    Ellen RL, Mcpherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81: 60B65B.
  • 293
    Hottelart C, El Esper N, Achard JM, Pruna A, Fournier A. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patinets with mild renal insufficicency]. Nephrologie 1999; 20: 4144.
  • 294
    Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999; 354: 219220.
  • 295
    Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 3944.
  • 296
    Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995; 99: 378385.
  • 297
    Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82: 29U34U.
  • 298
    Gokal R, Mann JI, Oliver DO, Ledingham JGG, Carter RD. Treatment of hyperlipidaemia in patients on chronic haemodialysis. BMJ 1978; 1: 8283.
  • 299
    Spratt P, Esmore D, Keogh A, Chang V. Comparison of three immunosuppressive protocols in cardiac transplantation. Transplant Proc 1989; 21: 24812483.
  • 300
    Chen HH, Lin LH. Recurrent pancreatitis secondary to type V hyperlipidemia: report of one case. Acta Paediatr Taiwan 2000; 41: 276278.
  • 301
    Colletti RB, Neufeld EJ, Roff NK, Mcauliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993; 92: 7882.
  • 302
    Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 1981; 112: 43.
  • 303
    Chicaud P, Demange J, Drouin P, Debry G. [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up]. Presse Med 1984; 13: 417419.
  • 304
    Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985; 60: 3437.
  • 305
    Kwiterovich PO Jr. Diagnosis and management of familial dyslipoproteinemia in children and adolescents. Pediatr Clin North Am 1990; 37: 14891523.
  • 306
    Enos WF, Holmes RH, Beyer J. Coronary artery diseas among United States soldiers killed in action in Korea. JAMA 1953; 152: 10901093.
  • 307
    Mcgill HC, Mcmahan CA, Herderick EE et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 2000; 20: 836845.
  • 308
    Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. New Engl J Med 1998; 338: 16501656.
  • 309
    Järvisalo MJ, Jartti L, Näntö-Salonen K et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 2001; 104: 29432947.
  • 310
    Kwiterovich PO, Barton BA, Mcmahon RP et al. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation 1997; 96: 25262533.
  • 311
    Niinikoski H, Viikari J, Ronnemaa T et al. Regulation of growth of 7- to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial. Pediatrics 1997; 100: 810816.
  • 312
    Niinikoski H, Koskinen P, Punnonen K et al. Intake and indicators of iron and zinc status in children consuming diets low in saturated fat and cholesterol: the STRIP baby study. Special Turku Coronary Risk Factor Intervention Project for Babies. Am J Clin Nutr 1997; 66: 569574.
  • 313
    Niinikoski H, Lapinleimu H, Viikari J et al. Growth until 3 years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. Pediatrics 1997; 99: 687694.
  • 314
    Lambert M, Lupien PJ, Gagne C et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996; 97: 619628.
  • 315
    Knipscheer HC, Boelen CC, Kastelein JJ et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867871.
  • 316
    Couture P, Brun LD, Szots F et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 10071012.
  • 317
    Vohl MC, Szots F, Lelie'vre M et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 160: 361368.
  • 318
    Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp Clin Res 1999; 25: 2328.
  • 319
    Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid–resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996; 10: 171174.
  • 320
    Sanjad SA, Al Abbad A, Al Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997; 130: 470474.
  • 321
    Kano K, Hoshi E, Ito S et al. Effects of combination therapy consisting of moderate-dose intravenous immunoglobulin G, pulsed methylprednisolone and pravastatin in children with steroid-resistant nephrosis. Nephron 2000; 84: 99100.
  • 322
    Marcucci R, Zanazzi M, Bertoni E et al. Risk factors for cardiovascular disease in renal transplant recipients: new insights. Transplant Int 2000; 13 (Suppl. 1): S419S424.
  • 323
    Stein EA, Illingworth DR, Kwiterovich PO Jr et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999; 281: 137144.
  • 324
    Knipscheer HC, Boelen CC, Kastelein JJ et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867871.
  • 325
    Mccrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 1997; 130: 266273.
  • 326
    West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 1980; 2: 873875.
  • 327
    West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975; 16: 9398.
  • 328
    Product Information Questran and Questran Light, 2000. Available at
  • 329
    Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics 1980; 65: 243250.
  • 330
    Schlierf G, Vogel G, Kohlmeier M, Vuilleumier JP, Huppe R, Schmidt-Gayk H. [Long-term therapy of familial hypercholesterolemia in young patients with colestipol: availability of minerals and vitamins]. Klin Wochenschr 1985; 63: 802806.
  • 331
    National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure. K/DOQI. Am J Kidney Dis 2000; 35: S1S140.
  • 332
    Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res 1995; 36: 18071812.
  • 333
    Williams CL, Bollella MC, Strobino BA, Boccia L, Campanaro L. Plant stanol ester and bran fiber in childhood. effects on lipids, stool weight and stool frequency in preschool children. J Am Coll Nutr 1999; 18: 572581.
  • 334
    Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 13081312.
  • 335
    Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 1998; 52: 334343.
  • 336
    Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr 2000; 130: 767776.